Familial association of histology specific breast cancers with cancers at other sites

International Journal of Cancer

Volumn 109, Issue 3, 2004, Pages 430-435

  Bermejo, Justo Lorenzo ^a   Hemminki, Kari ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Breast cancer histology; Comedo breast cancer; Familial risk; Medullary breast cancer; Sibling risk

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BREAST CANCER; CALCULATION; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER REGISTRY; CANCER RISK; CHILD; COLON CANCER; COMEDO; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; FAMILIAL CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFANT; LARYNX CANCER; LEUKEMIA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NEWBORN; OVARY CANCER; PANCREAS CANCER; PARENT; PRIORITY JOURNAL; PROSTATE CANCER; SIBLING; SKIN CANCER; SQUAMOUS CELL CARCINOMA; STANDARDIZATION; SWEDEN;

AGED; BREAST NEOPLASMS; DATABASES, GENETIC; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HISTOLOGY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; RISK FACTORS;

EID: 1342267052     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11713     Document Type: Article

References (45)

1. Dite GS, Jenkins MA, Southey MC, Hocking JS, Giles GG, McCredie MR, Venter DJ, Hopper JL. Familial risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations. J Natl Cancer Inst 2003;95:448-57.
2. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994;343:692-5.
3. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
4. Lin KM, Ternent CA, Adams DR, Thorson AG, Blatchford GJ, Christensen MA, Watson P, Lynch HT. Colorectal cancer in hereditary breast cancer kindreds. Dis Colon Rectum 1999;42:1041-5.
5. Johannsson O, Loman N, Moller T, Kristoffersson U, Borg A, Olsson H. Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers. Eur J Cancer 1999;35:1248-57.
6. Langston AA, Stanford JL, Wicklund KG, Thompson JD, Blazej RG, Ostrander EA. Germ-line BRCA1 mutations in selected men with prostate cancer. Am J Hum Genet 1996;58:881-4.
7. Lehrer S, Fodor F, Stock RG, Stone NN, Eng C, Song HK, McGovern M. Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer. Br J Cancer 1998;78:771-3.
8. Goldgar DE, Neuhausen SL, Steele L, Fields P, Ward JH, Tran T, Ngyuen K, Stratton MR, Easton DF. A 45-year follow-up of kindred 107 and the search for BRCA2. J Natl Cancer Inst Monogr 1995:15-9.
9. Gudmundsson J, Johannesdottir G, Bergthorsson JT, Arason A, Ingvarsson S, Egilsson V, Barkardottir RB. Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13. Cancer Res 1995;55:4830-2.
10. Tonin P, Ghadirian P, Phelan C, Lenoir GM, Lynch HT, Letendre F, Belanger D, Monte M, Narod SA. A large multisite cancer family is linked to BRCA2. J Med Genet 1995;32:982-4.
11. Katagiri T, Nakamura Y, Miki Y. Mutations in the BRCA2 gene in hepatocellular carcinomas. Cancer Res 1996;56:4575-7.
12. Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM, Yeo CJ, Jackson CE, Lynch HT, Hruban RH, Kern SE. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996;56:5360-4.
13. Tonin P, Weber B, Offit K, Couch F, Rebbeck TR, Neuhausen S, Godwin AK, Daly M, Wagner-Costalos J, Berman D, Grana G, Fox E et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 1996;2:1179-83.
14. Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, Tulinius H, Ogmundsdottir HM, Eyfjord JE. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 1996;13:117-9.
15. Phelan CM, Lancaster JM, Tonin P, Gumbs C, Cochran C, Carter R, Ghardirian P, Perret C, Moslehi R, Dion F, Faucher MC, Dole K et al. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet 1996;13:120-2.
16. Easton DF, Steele L, Fields P, Ormiston W, Averill D, Daly PA, McManus R, Neuhausen SL, Ford D, Wooster R, Cannon-Albright LA, Stratton MR et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet 1997;61:120-8.
17. Tulinius H, Egilsson V, Olafsdottir GH, Sigvaldason H. Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. Br Med J 1992;305:855-7.
18. Wilkens EP, Freije D, Xu J, Nusskern DR, Suzuki H, Isaacs SN, Wiley K, Bujnovsky P, Meyers DA, Walsh PC, Isaacs WB. No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer. Prostate 1999;39:280-4.
19. Sinclair CS, Berry R, Schaid D, Thibodeau SN, Couch FJ. BRCA1 and BRCA2 have a limited role in familial prostate cancer. Cancer Res 2000;60:1371-5.
20. Nastiuk KL, Mansukhani M, Terry MB, Kularatne P, Rubin MA, Melamed J, Gammon MD, Ittmann M, Krolewski JJ. Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men. Prostate 1999;40:172-7.
21. Russo J, Russo IH. Cellular basis of breast cancer susceptibility. Oncol Res 1999;11:169-78.
22. Lakhani SR, Gusterson BA, Jacquemier J, Sloane JP, Anderson TJ, van de Vijver MJ, Venter D, Freeman A, Antoniou A, McGuffog L, Smyth E, Steel CM et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 2000;6:782-9.
23. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, Farid LM, Venter D, Antonious A, Storfer-Isser A, Smyth E, Steel CM et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998;90:1138-45.
24. Hemminki K, Vaittinen P. National database of familial cancer in Sweden. Genet Epidemiol 1998;15:225-36.
25. Cancer incidence in Sweden, 2000 Stockholm, National Board of Health and Welfare, 2002, 2002:118.
26. Esteve J, Benhamou E, Raymond L. Statistical methods in cancer research. Volume IV. Descriptive epidemiology. IARC Sci Publ 1994; 1-302.
27. Tukey JW. Some thoughts on clinical trials, especially problems of multiplicity. Science 1977;198:679-84.
28. Hemminki K, Vaittinen P, Dong C, Easton D. Sibling risks in cancer: clues to recessive or X-linked genes? Br J Cancer 2001;84:388-91.
29. Guo SW. Inflation of sibling recurrence-risk ratio, due to ascertainment bias and/or overreporting. Am J Hum Genet 1998;63:252-8.
30. Olson JM, Cordell HJ. Ascertainment bias in the estimation of sibling genetic risk parameters. Genet Epidemiol 2000;18:217-35.
31. Dong C, Hemminki K. Modification of cancer risks in offspring by sibling and parental cancers from 2,112,616 nuclear families. Int J Cancer 2001;92:144-50.
32. Hamajima N, Hirose K, Tajima K, Rohan T, Calle EE, Heath CW, Jr., Coates RJ, Liff JM, Talamini R, Chantarakul N, Koetsawang S, Rachawat D et al. Alcohol, tobacco and breast cancer: collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer 2002;87:1234-45.
33. Di Leo A, Messa C, Cavallini A, Linsalata M. Estrogens and colorectal cancer. Curr Drug Targets Immune Endocr Metabol Disord 2001;1:1-12.
34. Varley JM. Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 2003;21:313-20.
35. Easton DF, Matthews FE, Ford D, Swerdlow AJ, Peto J. Cancer mortality in relatives of women with ovarian cancer: the OPCS Study. Office of Population Censuses and Surveys. Int J Cancer 1996;65:284-94.
36. Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer 1997;71:800-9.
37. Verkooijen HM, Fioretta G, Vlastos G, Morabia A, Schubert H, Sappino AP, Pelte MF, Schafer P, Kurtz J, Bouchardy C. Important increase of invasive lobular breast cancer incidence in Geneva, Switzerland. Int J Cancer 2003;104:778-81.
38. Li CI, Anderson BO, Porter P, Holt SK, Daling JR, Moe RE. Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer 2000;88:2561-9.
39. Li CI, Weiss NS, Stanford JL, Daling JR. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer 2000;88:2570-7.
40. Claus EB, Risch N, Thompson WD, Carter D. Relationship between breast histopathology and family history of breast cancer. Cancer 1993;71:147-53.
41. Tavassoli FA. Pathology of advanced primary breast carcinoma. Surg Oncol Clin N Am 1995;4:591-600.
42. Newcomer LM, Newcomb PA, Trentham-Dietz A, Storer BE, Yasui Y, Daling JR, Potter JD. Detection method and breast carcinoma histology. Cancer 2002;95:470-7.
43. Hemminki K, Granstrom C. Morphological types of breast cancer in family members and multiple primary tumours: is morphology genetically determined? Breast Cancer Res 2002;4:R7.
44. Hemminki K, Granstrom C. Familial breast carcinoma risks by morphology: a nationwide epidemiologic study from Sweden. Cancer 2002;94:3063-70.
45. Hemminki K, Granstrom C, Czene K. Attributable risks for familial breast cancer by proband status and morphology: a nationwide epidemiologic study from Sweden. Int J Cancer 2002;100:214-9.